(0.51%) 5 214.08 points
(0.85%) 39 388 points
(0.27%) 16 346 points
(0.49%) $79.65
(0.48%) $2.31
(0.59%) $2 354.00
(0.60%) $28.54
(0.35%) $994.30
(0.04%) $0.928
(-0.19%) $10.85
(0.02%) $0.799
(-0.02%) $92.52
3 days till quarter result
(bmo 2024-05-13)
Expected move: +/- 9.08%
Live Chart Being Loaded With Signals
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals...
Stats | |
---|---|
今日成交量 | 54 716.00 |
平均成交量 | 157 504 |
市值 | 35.07M |
EPS | $0 ( 2024-03-27 ) |
下一个收益日期 | ( $-0.210 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.940 |
ATR14 | $0.00900 (0.80%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-06-21 | Robertson Judith J. | Buy | 5 500 | Stock Option (right to buy) |
2023-06-21 | Maderis Gail J | Buy | 5 500 | Stock Option (right to buy) |
2023-06-21 | Garcia Peter S | Buy | 5 500 | Stock Option (right to buy) |
2023-06-21 | Farfel Gail M | Buy | 5 500 | Stock Option (right to buy) |
2023-06-21 | Blaschke Terrence F | Buy | 5 500 | Stock Option (right to buy) |
INSIDER POWER |
---|
99.11 |
Last 97 transactions |
Buy: 5 988 954 | Sell: 1 498 606 |
音量 相关性
DURECT Corp 相关性 - 货币/商品
DURECT Corp 财务报表
Annual | 2023 |
营收: | $8.55M |
毛利润: | $6.83M (79.91 %) |
EPS: | $-1.050 |
FY | 2023 |
营收: | $8.55M |
毛利润: | $6.83M (79.91 %) |
EPS: | $-1.050 |
FY | 2022 |
营收: | $19.28M |
毛利润: | $17.70M (91.76 %) |
EPS: | $-1.560 |
FY | 2021 |
营收: | $13.98M |
毛利润: | $12.02M (86.01 %) |
EPS: | $-0.0161 |
Financial Reports:
No articles found.
DURECT Corp
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。